Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (338) Arrow Down
Filter Results: (338) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (338)
    • News  (34)
    • Research  (273)
  • Faculty Publications  (228)

Show Results For

  • All HBS Web  (338)
    • News  (34)
    • Research  (273)
  • Faculty Publications  (228)
← Page 15 of 338 Results →
  • December 2017 (Revised January 2018)
  • Case

Alltech

By: David E. Bell and Natalie Kindred
Alltech was a Lexington, Kentucky–based producer of supplements for animal feed, with revenues of over $2 billion (projected to reach $3 billion in 2018), sales in 120 countries, 5,000 employees, and 100 manufacturing plants worldwide. For nearly four decades, Alltech... View Details
Keywords: Alltech; United States; Agribusiness; Agriculture; Animal; Animal Agriculture; Animal Feed; Livestock; Family Business; Vertical Integration; Strategy; Growth; Feed Additives; Feed Supplements; Kentucky; Growth Strategy; Family Businesses; Animal-Based Agribusiness; Acquisition; Business Growth and Maturation; Business Model; Change Management; Trends; Governance; Entrepreneurship; Growth and Development; Intellectual Property; Leadership; Management; Markets; Organizational Culture; Private Ownership; Science; Quality; Risk and Uncertainty; Research; Sales; Pharmaceutical Industry; Pharmaceutical Industry; United States; Kentucky; Brazil; China
Citation
Educators
Purchase
Related
Bell, David E., and Natalie Kindred. "Alltech." Harvard Business School Case 518-001, December 2017. (Revised January 2018.)
  • July 2016 (Revised July 2019)
  • Teaching Plan

Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)

By: Nori Gerardo Lietz and Ricardo Andrade
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers & Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Purchase
Related
Lietz, Nori Gerardo, and Ricardo Andrade. "Doctor My Eyes: The Acquisition of Bausch & Lomb by Warburg Pincus (A)." Harvard Business School Teaching Plan 217-003, July 2016. (Revised July 2019.)
  • April 2016 (Revised July 2019)
  • Case

"Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A)

By: Nori Gerardo Lietz
In early 2010, senior partners at Warburg Pincus met to review a report on Bausch & Lomb Incorporated, the firm's largest investment at the time. Warburg Pincus had led a group of investors in acquiring Bauch & Lomb on October 26, 2007, taking the company private and... View Details
Keywords: Health Care; Mergers & Acquisitions; Governance; Buyout; Private Equity; Finance; Mergers and Acquisitions; Corporate Governance; Health Care and Treatment; Reports; Business Model; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Educators
Related
Lietz, Nori Gerardo. "Doctor My Eyes"--The Acquisition of Bausch & Lomb by Warburg Pincus (A). Harvard Business School Case 216-021, April 2016. (Revised July 2019.)
  • April 2022
  • Teaching Note

CVS Health: Prescription for Transformation

By: Rosabeth Moss Kanter and Catarina Martinez
In 2021, new CEO Karen Lynch (named the most powerful woman in business) considered the next transformation phase for CVS Health (a Fortune 5 corporate giant). The 2018 acquisition of Aetna insurance brought her to the company as part of its long evolution from a... View Details
Keywords: Health; COVID-19 Pandemic; Primary Care; Leadership; Change Management; Women Executives; Retail; Pharmacy; Pharmacy Benefit Manager; Clinical Trials; Vaccination; Acquisition; Innovation and Invention; Transformation; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Purchase
Related
Kanter, Rosabeth Moss, and Catarina Martinez. "CVS Health: Prescription for Transformation." Harvard Business School Teaching Note 322-122, April 2022.
  • May 2018
  • Case

The Multiple Myeloma Research Foundation's Answer Fund

By: Richard G. Hamermesh and Matthew G. Preble
Keywords: Data Analytics; Customer Focus and Relationships; Customer Relationship Management; Cost vs Benefits; Investment Return; Health Care and Treatment; Innovation Leadership; Intellectual Property; Knowledge Sharing; Knowledge Dissemination; Leadership; Leading Change; Resource Allocation; Goals and Objectives; Marketing Communications; Performance; Programs; Projects; Business and Community Relations; Business and Stakeholder Relations; Networks; Partners and Partnerships; Research and Development; Genetics; Behavior; Motivation and Incentives; Social and Collaborative Networks; Nonprofit Organizations; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Educators
Related
Hamermesh, Richard G., and Matthew G. Preble. "The Multiple Myeloma Research Foundation's Answer Fund." Harvard Business School Case 818-045, May 2018.
  • January 2014
  • Supplement

Amgen Inc.: Pursuing Innovation and Imitation? (B)

By: Ian Mackenzie
The (B) case reveals that Sharer decided that Amgen should enter the emerging biosimilars business. However, he took the better part of a year to syndicate the decision across the senior team while in parallel investing in some time-critical process development. The... View Details
Keywords: Corporate Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Purchase
Related
Mackenzie, Ian. "Amgen Inc.: Pursuing Innovation and Imitation? (B)." Harvard Business School Supplement 714-426, January 2014.
  • May 2012 (Revised August 2014)
  • Case

McKesson

By: Regina E. Herzlinger and Natalie Kindred
McKesson, a large, diversified drug distribution and health care IT company, is considering development of new business offerings to help private practice physicians remain independent. The company, with $122 billion in 2010 revenues, just made its first foray into... View Details
Keywords: Health Care Industry; Health Care Policy; Organizational Transformations; Health Services; Health Care and Treatment; Business Model; Service Operations; Change Management; Corporate Strategy; Information Technology; Policy; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Herzlinger, Regina E., and Natalie Kindred. "McKesson." Harvard Business School Case 312-002, May 2012. (Revised August 2014.)
  • December 2005 (Revised October 2006)
  • Case

Pharmacy Service Improvement at CVS (A)

CVS's retail pharmacy operations are functioning poorly and dissatisfying customers. Many customers are defecting as a result. A pharmacy service improvement team has documented the current prescription fulfillment process, its exception rates, and the problems... View Details
Keywords: Information Technology; Performance Improvement; Business Processes; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
McAfee, Andrew P. "Pharmacy Service Improvement at CVS (A)." Harvard Business School Case 606-015, December 2005. (Revised October 2006.)
  • April 1993 (Revised May 1994)
  • Case

Genzyme Corporation: Strategic Challenges with Ceredase

Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has... View Details
Keywords: Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States
Citation
Educators
Purchase
Related
Teisberg, Elizabeth O., and Sharon L. Rossi. "Genzyme Corporation: Strategic Challenges with Ceredase." Harvard Business School Case 793-120, April 1993. (Revised May 1994.)
  • 18 Jul 2018
  • Research & Ideas

No More General Tso's? A Threat to 'Knowledge Recombination'

pharmaceutical companies, which had been flying in scientists from China and India who, like Cohly, brought knowledge of native herbs. Some pharma companies were able to earn exemptions from the H1-B limits. Choudhury and Kim used this... View Details
Keywords: by Michael Blanding; Health; Food & Beverage; Accounting
  • 01 Sep 2012
  • News

What’s the Big Idea?

international divisions. “Goldman Sachs in New York is different from Goldman Sachs in Asia,” he observes, adding that the same is true for conglomerates operating in industries as different as pharmaceuticals and aircraft engines.... View Details
Keywords: Garry Emmons;Julia Hanna;Roger Thompson; Corporate Services; Colleges, Universities, and Professional Schools; Educational Services; Management
  • 03 Jan 2007
  • First Look

First Look: January 3, 2007

analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's... View Details
Keywords: Sean Silverthorne
  • 01 Jul 2008
  • First Look

First Look: July 1, 2008

establish a proposed alliance with a pharmaceutical firm? Should it create a nutraceuticals business in parallel to its effort to develop anti-aging therapeutics? And, should it in-license a second drug development candidate? Purchase... View Details
Keywords: Martha Lagace
  • May 1992
  • Teaching Note

RU 486 (A) and (B), Teaching Note

By: Joseph L. Badaracco Jr.
Teaching Note for (9-391-050) and (9-391-051). View Details
Keywords: Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States
Citation
Purchase
Related
Badaracco, Joseph L., Jr. "RU 486 (A) and (B), Teaching Note." Harvard Business School Teaching Note 392-147, May 1992.
  • October 1990 (Revised April 1991)
  • Case

RU 486 (A)

By: Joseph L. Badaracco Jr.
Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its... View Details
Keywords: Judgments; Ethics; Product Launch; Negotiation; Outcome or Result; Performance; Business and Government Relations; Pharmaceutical Industry; Pharmaceutical Industry; France; Germany; United States
Citation
Educators
Purchase
Related
Badaracco, Joseph L., Jr. "RU 486 (A)." Harvard Business School Case 391-050, October 1990. (Revised April 1991.)
  • 01 Dec 2001
  • News

Reaching Out

Ph.D. in pathology and molecular biology at Boston University's School of Medicine. Intrigued by his experience with pharmaceutical companies and the role of business in drug delivery, he enrolled at HBS one month after finishing his... View Details
Keywords: Garry Emmons and Julia Hanna; Health, Social Assistance
  • January 2023
  • Teaching Note

The Opioid Settlement and Executive Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
Citation
Purchase
Related
Srinivasan, Suraj, and Li-Kuan Ni. "The Opioid Settlement and Executive Pay at AmerisourceBergen." Harvard Business School Teaching Note 123-067, January 2023.
  • 26 Apr 2023
  • Cold Call Podcast

How Martine Rothblatt Started a Company to Save Her Daughter

Keywords: Re: Debora L. Spar; Pharmaceutical; Pharmaceutical; Pharmaceutical
  • 13 Jan 2009
  • First Look

First Look: January 13, 2009

drive HNA's continued growth. Purchase this case: http://harvardbusinessonline.hbsp.harvard.edu/ b01/en/common/item_detail.jhtml?id=309029 Maggie Lena Walker and the Independent Order of St. Luke Harvard Business School Case 409-057 As View Details
Keywords: Martha Lagace
  • 20 Feb 2018
  • First Look

First Look at New Research and Ideas, February 20, 2018

the end of the one-child policy, and ethnic tensions. Others focus on China’s relationship with other nations, particularly the United States. If America pulls back from its Asian commitments, how will China assert its growing strength in... View Details
Keywords: Sean Silverthorne
  • ←
  • 15
  • 16
  • 17
  • →
ǁ
Campus Map
Harvard Business School
Soldiers Field
Boston, MA 02163
→Map & Directions
→More Contact Information
  • Make a Gift
  • Site Map
  • Jobs
  • Harvard University
  • Trademarks
  • Policies
  • Accessibility
  • Digital Accessibility
Copyright © President & Fellows of Harvard College.